PortfoliosLab logoPortfoliosLab logo
CNTB vs. CTMX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CNTB vs. CTMX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Connect Biopharma Holdings Limited (CNTB) and CytomX Therapeutics, Inc. (CTMX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

The year-to-date returns for both stocks are quite close, with CNTB having a -25.89% return and CTMX slightly lower at -26.06%.


CNTB

1D
5.03%
1M
-11.06%
YTD
-25.89%
6M
-19.62%
1Y
3Y*
5Y*
10Y*

CTMX

1D
3.62%
1M
-16.22%
YTD
-26.06%
6M
-25.00%
1Y
45.83%
3Y*
26.94%
5Y*
-14.01%
10Y*
-10.76%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CNTB vs. CTMX - Yearly Performance Comparison


2026 (YTD)2025
CNTB
Connect Biopharma Holdings Limited
-25.89%28.18%
CTMX
CytomX Therapeutics, Inc.
-26.06%104.81%

Correlation

The correlation between CNTB and CTMX is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (All Time)
Calculated using the full available price history since Sep 3, 2025

0.25

Fundamentals

Market Cap

CNTB:

$116.33M

CTMX:

$558.41M

EPS

CNTB:

-$1.28

CTMX:

-$0.37

PS Ratio

CNTB:

4.46

CTMX:

14.21

PB Ratio

CNTB:

2.77

CTMX:

1.75

Total Revenue (TTM)

CNTB:

$26.03M

CTMX:

$35.54M

Gross Profit (TTM)

CNTB:

$25.37M

CTMX:

$24.77M

EBITDA (TTM)

CNTB:

-$72.75M

CTMX:

-$62.07M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CNTB vs. CTMX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNTB

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.


CTMX
CTMX Risk / Return Rank: 6262
Overall Rank
CTMX Sharpe Ratio Rank: 5959
Sharpe Ratio Rank
CTMX Sortino Ratio Rank: 6666
Sortino Ratio Rank
CTMX Omega Ratio Rank: 6565
Omega Ratio Rank
CTMX Calmar Ratio Rank: 6060
Calmar Ratio Rank
CTMX Martin Ratio Rank: 6161
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNTB vs. CTMX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Connect Biopharma Holdings Limited (CNTB) and CytomX Therapeutics, Inc. (CTMX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CNTBCTMXDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.19

Calmar ratioReturn relative to maximum drawdown

0.81

Martin ratioReturn relative to average drawdown

1.89

CNTB vs. CTMX - Sharpe Ratio Comparison


Loading charts...

Drawdowns

CNTB vs. CTMX - Drawdown Comparison

The maximum CNTB drawdown since its inception was -46.07%, smaller than the maximum CTMX drawdown of -98.74%. Use the drawdown chart below to compare losses from any high point for CNTB and CTMX.


Loading charts...

Drawdown Indicators


CNTBCTMXDifference

Max Drawdown

Largest peak-to-trough decline

-46.07%

-98.74%

+52.67%

Max Drawdown (1Y)

Largest decline over 1 year

-56.89%

Max Drawdown (3Y)

Largest decline over 3 years

-91.59%

Max Drawdown (5Y)

Largest decline over 5 years

-94.16%

Max Drawdown (10Y)

Largest decline over 10 years

-98.74%

Current Drawdown

Current decline from peak

-43.36%

-90.79%

+47.43%

Average Drawdown

Average peak-to-trough decline

-23.81%

-70.94%

+47.13%

Ulcer Index

Depth and duration of drawdowns from previous peaks

24.26%

Volatility

CNTB vs. CTMX - Volatility Comparison


Loading charts...

Volatility by Period


CNTBCTMXDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.67%

Volatility (6M)

Calculated over the trailing 6-month period

67.16%

Volatility (1Y)

Calculated over the trailing 1-year period

93.84%

93.70%

+0.14%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

93.84%

141.88%

-48.04%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

93.84%

111.37%

-17.53%

Dividends

CNTB vs. CTMX - Dividend Comparison

Neither CNTB nor CTMX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

CNTB vs. CTMX - Financials Comparison

This section allows you to compare key financial metrics between Connect Biopharma Holdings Limited and CytomX Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00M20.00M30.00M40.00M50.00M202120222023202420252026
-48.00K
10.26M
(CNTB) Total Revenue
(CTMX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


CNTB and CTMX have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for CNTB and CTMX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer